Preview

Rational Pharmacotherapy in Cardiology

Advanced search

The Role of Rivaroxaban in a Comprehensive Protection Strategy for Patients with Atrial Fibrillation

https://doi.org/10.20996/1819-6446-2021-04-17

Full Text:

Abstract

Anticoagulant therapy of patients with atrial fibrillation is an integral part of their treatment strategy. The high risk of developing a cardioembolic stroke and the high comorbidity of this group of patients necessitates a comprehensive approach to treatment, taking into account all available risk factors. Atrial fibrillation is often asymptomatic and timely detection of these patients can be one of the most important tasks in the complex of measures aimed at protecting patients from stroke. The European Society of Cardiology's 2020 guidelines suggest the use of a CC to ABC patient management strategy. This strategy involves a number of measures aimed at managing atrial fibrillation, including confirming the diagnosis, determining the characteristics of atrial fibrillation and treatment tactics. One of the points of this strategy is the control of comorbidities and risk factors for cardiovascular diseases. To date, rivaroxaban has a number of convincing and reliable data on a high profile of efficacy and safety in the treatment of comorbid patients who not only have a high risk of stroke, but also need protection from coronary events and decreased renal filtration function. These data are confirmed by both the results of randomized clinical trials and data from real clinical practice. The review discusses the literature data describing the condition of patients with atrial fibrillation while taking direct oral anticoagulants, according to the search query “Atrial fibrillation, effectiveness and safety of rivaroxaban, warfarin, comorbidity, atrial fibrillation, efficacy and safety of rivaroxaban, warfarin, comorbid status” for the period from 2010 to 2020 in open sources PubMed and e-library, and a strategy for the comprehensive protection of patients with atrial fibrillation when using rivaroxaban is proposed for consideration.

About the Authors

I. A. Zolotovskaya
Samara State Medical University
Russian Federation

Irina A. Zolotovskaya

Samara



V. D. Sabanova
Samara State Medical University
Russian Federation

Victoria D. Sabanova

Samara



I. L. Davydkin
Samara State Medical University
Russian Federation

 

Igor L. Davydkin

Samara



References

1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: theAnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001;285(18):2370-5. DOI:10.1001/jama.285.18.2370.

2. Colilla S, Crow A, Petkun W, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the US adult population. Am J Cardiol. 2013;112(8):1142-7. DOI:10.1016/j.amj-card.2013.05.063.

3. Borre ED, Goode A, Raitz G, et al. Predicting Thromboembolic and Bleeding Event Risk in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review. Thromb Haemost. 2018;118(12):2171-87. DOI:10.1055/s-0038-1675400.

4. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2014;129:837-47. DOI:10.1161/CIRCULATION-AHA.113.005119.

5. Stakhanovskaya LV, Klochihina OA, Korotkevich IA, et al. Analysis of prognostic indicators-predictors of death in stroke patients. Astrakhan Medical Journal. 2018;13(2):97-103 (In Russ.) DOI:10.17021/2018.13.2.97.103.

6. Zolotovskaia IA, Davydkin IL. The concept of the multiplicative effect of the risk ofrecurrent throm-boembolism in patients with atrial fibrillation. Siberian Medical Journal (Irkutsk). 2016;141(2):28- 32 (In Russ.)

7. Jawad-Ul-Qamar M, Kirchhof P. Almanac 2015: atrial fibrillation research in Heart. Heart. 2016;102:573-80. DOI:10.1136/heartjnl-2015-307809.

8. Poteshkina NG, Troshina AA, Maslova MY. Antithrombotic therapy in the prevention of stroke in elderly patients with atrial fibrillation. Clinical Gerontology. 2019;25(7-8):54-60 (In Russ.) DOI:10.26347/1607-2400201907-08054-060.

9. Ibragimova GZ, Sabirova AR, Bilalova RR, et al. Risk factors of ischemic cardioembolic stroke. The Bulletin of Contemporary Clinical Medicine. 2019;12(5):20-4 (In Russ.) DOI:10.20969/VSKM.2019.12(5).20-24.

10. Guo Y, Wang H, Tian Y, et al. Multiple risk factors and ischaemic stroke in the elderly Asian population with and without atrial fibrillation. An analysis of 425,600 Chinese individuals without prior stroke. Thromb Haemost. 2016;115(1):184-192. DOI:10.1160/TH15-07-0577.

11. Y Guo, J Guo, X Shi, et al. Mobile health technology-supported atrial fibrillation screening and inte-grated care: A report from the mAFA-II trial Long-term Extension Cohort. European Journal of Internal Medicine.2020;82:105-11. DOI:10.1016/j.ejim.2020.09.024.

12. Gudmundsdottir KK, Fredriksson T, Svennberg Eet al. Stepwise mass screening for atrial fibrillation using N-terminal B-type natriuretic peptide: the STROKESTOP II study. Europace. 2020;22:24-32. DOI:10.1093/europace/euz255.

13. Devyashina KS, Oganyan KG, Panchoyan SM, et al. The possibility of early diagnostics of atrial fibrillation in patients with high risk of it's development. Russian Family Doctor. 2018; 22(2):14-8 (In Russ.) DOI:10.17816/RFD2018214-18.

14. Bertaglia E, Blank B, Blomstrdm-Lundqvist C, et al. Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence. Europace. 2019;21(10):1459-67. DOI:10.1093/europace/euz172.

15. Atrial fibrillation and flutter in adults. Clinical guidelines. Available from: https://sudact.ru/law/klinicheskie-rekomendatsii-fibrilliatsiia-i-trepetanie-predserdii-u/] (In Russ.)

16. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020;ehaa612. DOI:10.1093/eurheartj/ehaa612.

17. Melnikov NP, Yashin SM. Atrial fibrillation in patients with chronic kidney disease. Journal of Arrhyth- mology. 2019;26(4):47-52 (In Russ.) DOI:10.35336/VA-2019-3-47-52.

18. Kirgizova MA, Batalov RE, Tatarsky BA, et al. Atrial fibrillation and hypertension: current understanding of the pathogenesis, diagnosis, and treatment. Siberian Medical Journal (Tomsk). 2019;34(3):13-20 (In Russ.) DOI:10.29001/2073-8552-2019-34-3-13-20.

19. Obrezan AG, Kulikov NV. Atrial fibrillation and diabetes mellitus: the control of thromboembolic risk. Kardiologiia. 2020;60(7):108-14 (In Russ.) DOI:10.18087/cardio.2020.7.n1146.

20. Fisher M, Moores L, Alsharif MN, et al. Definition and Implications of the Preventable Stroke. JAMA Neurol. 2015;73:186-9. DOI:10.1001/jamaneurol.2015.3587.

21. National Clinical Guideline Centre (UK). National Clinical Guideline Centre: Atrial fibrillation: the management of atrial fibrillation. Clinical guideline: Methods, evidence and recommendations. London: National Institute for Health and Care Excellence (UK); 2014.

22. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-8. DOI:10.1161/01.STR.22.8.983.

23. Sposato LA, Riccio PM, Hachinski VH. Poststroke atrial fibrillation: cause or consequence? Critical review of current views. Neurology. 2014;82:1180-6. DOI:10.1212/WNL.0000000000000265.

24. Sposato LA, Cipriano LE, Saposnik G, et al. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol. 2015;14:377-87. DOI:10.1016/S1474-4422(15)70027-X.

25. Cerasuolo JO, Cipriano LE, Sposato LA. The complexity of atrial fibrillation newly diagnosed after ischemic stroke and transient ischemic attack: advances and uncertainties. Curr Opin Neurol. 2017;30(1):28-37. DOI:10.1097/WCO.0000000000000410.

26. Chiang CE, Okumura K, Zhang S, et al. 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. J Arrhythm. 2017;33(4):345-367. DOI:10.1016/j.joa.2017.05.004.

27. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893-962. DOI:10.5603/KP.2016.0172.

28. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86. DOI:10.1136/bmj.324.7329.71.

29. Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev.2007;(3):CD006186. DOI:10.1002/14651858.CD006186.pub2.

30. Xue Z, Zhang H. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Asians With Atrial Fibrillation: Meta-Analysis of Randomized Trials and Real-World Studies. Stroke. 2019;50(10):2819- 28. DOI:10.1161/STROKEAHA.119.026054.

31. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine. 2011;365(10):883-91. DOI:10.1056/NEJMoa1009638.

32. Turakhia MP, Blankestijn PJ, Carrero JJ, et al. Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Eur Heart J. 2018;39(24):2314-25. DOI:10.1093/eurheartj/ehy060.

33. Fox KAA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32(19):2387-94. DOI:10.1093/eurheartj/ehr342.

34. Halperin JL, Hankey GJ, Wojdyla DM, et al. Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) 2014;130(2):138-46. DOI:10.1161/CIRCULATION- AHA.113.005008.

35. Kirchhof P, Radaideh G, Kim YH, et al. Global Prospective Safety Analysis of Rivaroxaban. J Am Coll Cardiol. 2018;72:141-53. DOI:10.1016/j.jacc.2018.04.058.

36. Camm AJ, Amarenco P, Haas S, et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2016;37:1145- 53. DOI:10.1093/eurheartj/ehv466.

37. Hanon О, Vidal JS, Pisica-Donose G, et al. Bleeding risk in elderly subjects more than 80 years in atrial fibrillation treated by rivaroxaban anticoagulant. Heart. 2020 Dec 1;heartjnl-2020-317923. doi: 10.1136/heartjnl-2020-317923.

38. Coleman CI, Weeda ER, Nguyen E, et al. Effectiveness and safety of rivaroxaban vs. warfarin in pa-tients 80+ years of age with non-valvular atrial fibrillation. Eur Heart J Qual Care Clin Outcomes. 2018;4(4):328-9. DOI:10.1093/ehjqcco/qcx044.

39. Martinez BK, Sood N, Bunz T, et al. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation. J Am Heart Assoc. 2018;7(8):e008643. DOI:10.1161/JAHA.118.008643.

40. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1- 76. DOI:10.1016/j.jacc.2014.03.022.

41. Inoue H, Nozawa T, Hirai T, et al. Accumulation of risk factors increases risk of thromboembolic events in patients with nonvalvular atrial fibrillation. Circ J.2006;70(6):651-6. DOI:10.1253/circj.70.651.

42. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093- 100. DOI:10.1378/chest.10-0134.

43. Gomez-Outes A, Terleira-Fernandez AI, Calvo-Rojas G, et al. Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups. Thrombosis. 2013;2013:640723. DOI:10.1155/2013/640723.

44. Proietti M, Laroche C, Opolski G, et al. “Real-world” atrial fibrillation management in Europe: obser-vations from the 2-year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase. Europace. 2017;19:722-33. DOI:10.1093/europace/euw112.

45. Makubi A, Hage C, Lwakatare J, et al. Contemporary aetiology, clinical characteristics and prognosis of adults with heart failure observed in a tertiary hospital in Tanzania: the prospective Tanzania Heart Failure (TaHeF) study. Heart. 2014;100:1235-41. DOI:10.1136/heartjnl-2014-305599.

46. Santhanakrishnan R, Wang N, Larson MG, et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation. 2016;133:484-92. DOI:10.1161/CIRCULATIONAHA.116.022835.

47. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37,2893-962. DOI:10.1093/eurheartj/ ehw210.

48. McManus DD, Saczynski JS, Lessard D, et al. Recent trends in the incidence, treatment, and prognosis of patients with heart failure and atrial fibrillation (the Worcester Heart Failure Study). Am J Cardiol. 2013;111:1460-5. DOI:10.1016/j.amjcard.2013.01.298.

49. Odutayo A, Wong CX, Williams R, et al. Prognostic Importance of Atrial Fibrillation Timing and Pattern in Adults With Congestive Heart Failure: A Systematic Review and Meta-Analysis. J Card Fail. 2017;23(1):56-62. DOI:10.1016/j.cardfail.2016.08.005.

50. Naito M, David D, Michelson EL, et al. The hemodynamic consequences of cardiac arrhythmias: evaluation of the relative roles of abnormal atrioventricular sequencing, irregularity of ventricular rhythm and atrial fibrillation in a canine model. Am Heart J. 1983;106(2):284-91. DOI:10.1016/0002-8703(83)90194-1.

51. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975. DOI:10.1093/eurheartj/ehw128.

52. Denham NC, Pearman CM, Caldwell JL, et al. Calcium in the Pathophysiology of Atrial Fibrillation and Heart Failure. Front Physiol. 2018;9:1380. DOI:10.3389/fphys.2018.01380.

53. Moiseev S. Which scores should use cardiologist to predict outcomes in patients with nonvalvular atrial fibrillation? Clin Pharmacol Ther. 2020;29(4):5-16 (In Russ.) DOI:10.32756/0869-5490-2020-4-516.

54. Pastori D, Farcomeni A, Poli D, et al. Cardiovascular risk stratification in patients with non-valvular atrial fibrillation: the 2MACE score. Intern Emerg Med. 2016;11(2):199-204. DOI:10.1007/s11739-015-1326-1.

55. Loukianov MM, Boytsov SA, Yakushin SS, et al. Diagnostics, treatment, associated cardiovascular and concomitant non-cardiac diseases in patients with diagnosis of “atrial fibrillation” in real outpa-tient practice (according to data of registry of cardiovascular diseases, RECVASA). Rational Pharmacotherapy in Cardiology. 2014;10(4):366-77 (In Russ.) DOI:10.20996/1819-6446-2014-10-4-366-377.

56. Mak KH. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open. 2012;2:e001592. DOI:10.1136/bmjopen-2012-001592.

57. Chatterjee S, Sharma A, Uchino K, et al. Rivaroxaban and risk of myocardial infarction: insights from a meta-analysis and trial sequential analysis of randomized clinical trials. Coron Artery Dis. 2013;24(8):628-35. DOI:10.1097/MCA.0000000000000031.

58. Loke YK, Pradhan S, Ka-Yan Yeong J, et al. Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison. Br J Clin Pharmacol. 2014 Oct;78(4):707-17. DOI:10.1111/bcp.12376.

59. Kupo P, Szaka Z, Solyma M, et al. Direct Anticoagulants and Risk of Myocardial Infarction, a Multiple Treatment Network Meta-Analysis Angiology. 2020;71(1):27-37. DOI:10.1177/0003319719874255.

60. Coleman CI, Baker WL, Meinecke AK, et al. Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease. Eur Heart J - Cardiovascular Pharmacotherapy. 2020;6:159-66. DOI:10.1093/ehjcvp/pvz047.

61. Sandhu RK, Kurth T, Conen D, et al. Relation of renal function to risk for incident atrial fibrillation in women. Am J Cardiol. 2012;109:538-42. DOI:10.1016/j.amjcard.2011.10.006

62. Shang W, Li L, Huang S, et al. Chronic kidney disease and the risk of new-onset atrial fibrillation: a meta-analysis of prospective cohort studies. PLoSOne. 2016;11:e0155581. DOI:10.1371/jour-nal.pone.0155581.

63. Alonso A, Krijthe BP, Aspelund T, et al.Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc. 2013;2:e000102. DOI:10.1161/JAHA.112.000102.

64. Brodsky S.V, Nadasdy T, Rovin B.H, et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int. 2011;80:181-9. DOI:10.1038/ki.2011.44.

65. Chatrou ML, Winckers K, Hackeng TM et al. Vascular calcification: the price to pay for anticoagulation therapy with vitamin K-antagonists. Blood Rev. 2012;26(4):155-66. DOI:10.1016/j.blre.2012.03.002.

66. Yao X, Tangri N, Gersh BJ, et al. Renal outcomes in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2017;70:2621-32. DOI:10.1016/j.jacc.2017.09.1087.

67. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125-51. DOI:10.1016/j.hrthm.2019.01.024.

68. Coleman CI, Kreutz R, Sood NA, et al. Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis. The American Journal of Medicine. 2019;132(9):1078-83. DOI:10.1016/j.amjmed.2019.04.013.

69. Chashkina MI, Kozlovskaya NL, Andreev DA, et al. Prevalence of Advanced Chronic Kidney Disease in Patients With Nonvalvular Atrial Fibrillation Hospitalized in Cardiology Departments. Kardiologiia. 2020;60(2):12-8 (In Russ.). DOI:10.18087/cardio.2020.2.n823.

70. Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33(22);2821-30. DOI:10.1093/eurheartj/ehs274.

71. Hijazi Z, Hohnloser SH, Oldgren J, et al. Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis. Circulation. 2014;129 (9):961-70. DOI:10.1161/CIRCULATIONAHA.113.003628.

72. Vermeer SE, Prins ND, den Heijer T, et al, Silent Brain Infarcts and the Risk of Dementia and Cognitive Decline. N Engl J Med. 2003;348:1215-22 DOI:10.1056/nejmoa022066.

73. Marzona I, O'Donnell M, Teo K, et al. Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies. CMAJ. 2012;184(6):E329- 36. DOI:10.1503/cmaj.111173.

74. Santangeli P, Di Biase L, Bai R, et al. Atrial fibrillation and the risk of incident dementia: A meta-analy- sis. Heart Rhythm. 2012;9(11):1761-8. DOI:10.1016/j.hrthm.2012.07.026.

75. Ten Cate V, ten Cate H, Verheugt FWA, et al. The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF). Neth Heart J. 2016;24:574-80. DOI:10.1007/s12471-016-0874-y.

76. O'Brien EC, Simon DN, Allen LA, et al. Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J. 2014;168:487-94. DOI:10.1016/j.ahj.2014.07.002.


For citation:


Zolotovskaya I.A., Sabanova V.D., Davydkin I.L. The Role of Rivaroxaban in a Comprehensive Protection Strategy for Patients with Atrial Fibrillation. Rational Pharmacotherapy in Cardiology. 2021;17(2):294-302. (In Russ.) https://doi.org/10.20996/1819-6446-2021-04-17

Views: 126


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)